Welcome to our dedicated page for Radiopharm Theranostics SEC filings (Ticker: RADX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Radiopharm Theranostics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Radiopharm Theranostics's regulatory disclosures and financial reporting.
Radiopharm Theranostics Limited furnished a Form 6-K to provide U.S. investors with a copy of an announcement previously released on the Australian Securities Exchange. The attached Exhibit 99.1 is a notification regarding the company’s unquoted securities. The filing is expressly treated as furnished, not filed, under U.S. securities laws.
Radiopharm Theranostics Limited filed a Form 6-K as a foreign private issuer to furnish a public notice previously released on the Australian Securities Exchange. The attached exhibit is an announcement dated October 1, 2025 titled “Radiopharm received approval for RAD 202 trial acceleration.” This means the company has received approval related to speeding up its RAD 202 trial and is sharing that information with U.S. investors. The Form 6-K states that this report, including the exhibit, is not deemed “filed” under the U.S. securities laws and will only be incorporated into other securities filings if later specifically referenced.
Radiopharm Theranostics Limited submitted a Form 6-K as a foreign private issuer, mainly to furnish an announcement it released to the Australian Securities Exchange. The exhibit, titled “Radiopharm Theranostics Partners with Starpharma on Research,” indicates the company has entered into a research-focused partnership with Starpharma, though specific terms are contained in the attached announcement rather than this summary document. The company also clarifies that this Form 6-K, including its exhibit, is being furnished rather than filed under U.S. securities laws and will only be incorporated into other securities filings if specifically referenced.
Radiopharm Theranostics Limited (RDPTF) reported a challenging year ending June 30, 2025, with a total comprehensive loss of A$37.88 million and negative operating cash flows of approximately A$36.65 million. The group recorded accumulated losses of A$145.73 million and significant research and development investment, including R&D expenses of A$27.52 million (line item) and intangible assets on the balance sheet of A$49.09 million.
The company generated other income including an R&D tax incentive (A$9.37 million recognised) and raised cash from financing activities (A$45.43 million reported in one table). Key governance and management details are disclosed, including CEO Riccardo Canevari and a Board with named directors and option/share holdings. The filing also discloses material contingent consideration balances, significant finance expenses and assumptions used in impairment and contingent consideration models.
Radiopharm Theranostics Limited submitted a Form 6-K as a foreign private issuer to provide U.S. investors with information it released on the Australian Securities Exchange. The filing furnishes as an exhibit a Public Notice dated September 17, 2025 titled “Corporate Governance Statement and Appendix 4G.”
The attached materials relate to the company’s corporate governance disclosures and associated compliance appendix. The Form 6-K and its exhibit are furnished, not filed, under U.S. securities laws, meaning they are not automatically incorporated by reference into other Securities Act filings unless specifically referenced.
Radiopharm Theranostics Limited submitted a Form 6-K to provide U.S. investors with a copy of an announcement it lodged with the Australian Securities Exchange. The filing mainly furnishes an exhibit describing a key opinion leader webinar titled “Pivalate (Brain Mets) key opinion leader webinar.”
The document clarifies that this Form 6-K, including the attached exhibit, is furnished rather than filed under U.S. securities laws and will only be incorporated into other U.S. filings if specifically referenced.
Radiopharm Theranostics Limited submitted a Form 6-K as a foreign private issuer to provide U.S. investors with information it released on the Australian Securities Exchange. The filing explains that the company published an announcement to the ASX on August 29, 2025 and attaches that disclosure as an exhibit. The exhibit, labeled 99.1, is the company’s Appendix 4E and preliminary final report. The company also notes that this Form 6-K, including the exhibit, is being furnished rather than filed under U.S. securities laws and will only be incorporated into other U.S. filings if specifically referenced.
Radiopharm Theranostics Limited furnished a Form 6-K to the U.S. Securities and Exchange Commission to share information previously announced on the Australian Securities Exchange. The filing attaches an announcement titled “Radiopharm to host key opinion leader webinar series” as an exhibit.
The company states that this Form 6-K and its exhibit are being furnished, not filed, under U.S. securities laws, meaning they are not automatically incorporated into other U.S. securities law filings unless specifically referenced.